Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Authors:
- James T. TophamJTJames T. Topham
- Haley M. BeckmannHBHaley M. Beckmann
- Joanna M. KarasinskaJKJoanna M. Karasinska
- Jonathan M. LoreeJLJonathan M. Loree
- Jennifer J. KnoxJKJennifer J. Knox
- Petr KavanPKPetr Kavan
- Derek JonkerDJDerek Jonker
- Stephen WelchSWStephen Welch
- Felix CoutureFCFelix Couture
- Frederic LemayFLFrederic Lemay
- Mustapha TehfeMTMustapha Tehfe
- Mohammed HarbMHMohammed Harb
Open Access
- 18 June 2026
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (16) , OF1-OF9
Abstract
Purpose: Pre-existing and emerging molecular targeted therapies have been identified for the treatment of pancreatic ductal adenocarcinoma (PDAC) and exemplify the need for incorporating tumor sequencing into routine clinical practice. Tumor profiling through circulating tumor DNA (ctDNA) represents an important opportunity in PDAC because of the aggressive nature of the disease. Circulating tumor fraction (CTF) levels are highly variable within and between cancer types and influence the accuracy of plasma-based tumor profiling, and the variability and factors related to CTF levels in PDAC are not well understood. Experimental Design: ctDNA sequencing (PredicineATLAS) and clinical metadata from a cohort of 166 patients with metastatic PDAC (mPDAC) were generated as part of the PA.7 trial (NCT02879318). Patients were stratified into high CTF (>30% CTF; 35/166, 21.08%) and low CTF (131/166, 78.92%) groups for comparative analysis. Matched RNA sequencing data were available for 20 patients. Results: High CTF was associated with lower overall survival (hazard ratio = 1.87; 95% confidence interval, 1.27–2.75; P = 0.0014) as well as clinical presentation that was indicative of higher disease burden, with CTF highest in patients that had liver metastases and distant metastases including bulky lymph nodes versus patients with no liver metastases (P < 0.001). Exploratory gene expression analysis revealed a positive association between CTF and upregulation of cell cycle–related pathways, which included those involving CDK4 (P = 0.0093) and MT2A (P = 0.012), as well as glycolytic (P = 0.0028) and basal-like (P = 0.029) subtyping genes. Conclusions: These data demonstrate the heterogeneity of CTF and its associated factors in mPDAC, which converge toward an aggressive phenotype from both clinical and molecular standpoints.Keywords
All Related Versions
Funding Information
- Terry Fox Research Institute (1078)
- Canadian Cancer Society (707213)
This publication has 37 references indexed in Scilit:
- Circulating tumour DNA (ctDNA) as a predictor of progression-free and overall survival in non-resectable pancreatic cancer: a systematic review and meta-analysisThe Journal of Liquid Biopsy, 2025
- Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapyCancer Cell, 2023
- Landscape of circulating tumour DNA in metastatic breast cancerEBioMedicine, 2020
- Cell-Free DNA and Apoptosis: How Dead Cells Inform About the LivingTrends in Molecular Medicine, 2020
- Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinomaInternational Journal of Cancer, 2019
- Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancerCancer Medicine, 2018
- Genomic analyses identify molecular subtypes of pancreatic cancerNature, 2016
- Liver Sinusoidal Endothelial CellsComprehensive Physiology, 2015
- Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinomaNature Genetics, 2015
- Sensitive detection of somatic point mutations in impure and heterogeneous cancer samplesNature Biotechnology, 2013